TF
NBIX icon

Trek Financial’s Neurocrine Biosciences NBIX Stock Holding History

Trek Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,135
Closed -$246K – 446
2024
Q3 		$246K Buy
2,135
+466
+28% +$63.9K 0.02% 344
2024
Q2 		$230K Sell
1,669
-388
-19% -$53.2K 0.02% 349
2024
Q1 		$284K Buy
+2,057
New +$281K 0.02% 319

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Trek Financial's NBIX Position: Q4 2024 in Review

Trek Financial sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 2,135 shares — an estimated $246K sold.

Trek Financial first reported a position in NBIX in Q1 2024 and held it in 3 quarters. The position peaked at $284K in Q1 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Trek Financial reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Trek Financial sold 2,135 Neurocrine Biosciences shares in Q4 2024, an estimated $246K.
  • Trek Financial first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 3 quarters.
  • Trek Financial's Neurocrine Biosciences position peaked at $284K in Q1 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Trek Financial's 13F filing for Q4 2024, filed 13 Feb 2025.